REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN US PLATINUM-RESISTANT OVARIAN CANCER PATIENTS: CHARACTERIZING THE UNMET CLINICAL NEED
Author(s)
Kathleen N. Moore, MD1, Kathleen M. McClain, PhD2, Helen Ding, MS, MSPH, MD3, Samantha N. Valliant, MS, PharmD4, Olga Tymejczyk, PhD5, Ke Meng, PhD3, Carsyn Norway, PharmD4, Yan xiong, PhD4, Elizabeth Marrett, PhD4, Boris Gorsh, PhD4, Matthew Monberg, PhD3, Ritu Salani, MD6;
1University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, 2Merck & Co., Inc., Associate Director, Oncology Portfolio RWE, Rahway, NJ, USA, 3Merck & Co., Inc., Rahway, NJ, USA, 4Daiichi Sankyo, Inc., Basking Ridge, NJ, USA, 5Daiichi Sankyo Inc, Basking Ridge, NJ, USA, 6University of California Los Angeles, Los Angeles, CA, USA
1University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, 2Merck & Co., Inc., Associate Director, Oncology Portfolio RWE, Rahway, NJ, USA, 3Merck & Co., Inc., Rahway, NJ, USA, 4Daiichi Sankyo, Inc., Basking Ridge, NJ, USA, 5Daiichi Sankyo Inc, Basking Ridge, NJ, USA, 6University of California Los Angeles, Los Angeles, CA, USA
OBJECTIVES: Platinum-resistant ovarian cancer (PROC) is an aggressive and recurrent gynecologic malignancy, with limited treatment options and poor outcomes. As emerging therapies become available, there is a need to characterize the current landscape of PROC through assessment of clinical outcomes, patient and clinical characteristics, and treatment patterns.
METHODS: This retrospective study used the US-based Flatiron Research Database. Adult patients with stage III/IV diagnosis on or after 05/01/2020, a platinum-containing first-line therapy (1L), and a first-eligible PROC line (2L-4L) were included. PROC was defined as a platinum-free interval of 90-180 days following 1L or ≤180 days following 2L/3L. The index line, line immediately following meeting PROC criteria, was started on or before 11/20/2024 to allow for ≥3 months of potential follow-up. Patients were followed through 02/28/2025. Descriptive analyses included patient demographic, clinical characteristics, and treatment patterns. Kaplan-Meier methods estimated real-world overall survival (rwOS), time to treatment discontinuation (rwTTD), and time to next treatment (rwTTNT).
RESULTS: Among 230 patients included, median age was 70 years, women were primarily treated within community practices (74%). Most were diagnosed 2020-2021 (53%), with equal distribution of stage III/IV, ECOG 0-1 (60%), and serous histology (77%). Majority were first identified as PROC at 2L (59.6%). BRCA testing was prevalent (94%), though few patients had a positive result (9%). Almost half of patients (47%) were tested for FRα expression, of which 35% had high expression, with 8% of patients treated with mirvetuximab soravtansine. Overall, 39% of patients initiated a non-platinum chemotherapy while 21% initiated a platinum-based chemotherapy; majority of all chemotherapy regimens were in combination with bevacizumab (66%). The time-to-event analyses revealed short rwTTD (3.3 [2.9, 3.7]), and rwTTNT (5.6 [4.9, 6.9]), and rwOS (median: 12.6 months [10.7, 16.6]).
CONCLUSIONS: In a real-world US PROC population, rwOS, rwTTD, and rwTTNT remain suboptimal, reflecting a high unmet need amid a diverse treatment landscape.
METHODS: This retrospective study used the US-based Flatiron Research Database. Adult patients with stage III/IV diagnosis on or after 05/01/2020, a platinum-containing first-line therapy (1L), and a first-eligible PROC line (2L-4L) were included. PROC was defined as a platinum-free interval of 90-180 days following 1L or ≤180 days following 2L/3L. The index line, line immediately following meeting PROC criteria, was started on or before 11/20/2024 to allow for ≥3 months of potential follow-up. Patients were followed through 02/28/2025. Descriptive analyses included patient demographic, clinical characteristics, and treatment patterns. Kaplan-Meier methods estimated real-world overall survival (rwOS), time to treatment discontinuation (rwTTD), and time to next treatment (rwTTNT).
RESULTS: Among 230 patients included, median age was 70 years, women were primarily treated within community practices (74%). Most were diagnosed 2020-2021 (53%), with equal distribution of stage III/IV, ECOG 0-1 (60%), and serous histology (77%). Majority were first identified as PROC at 2L (59.6%). BRCA testing was prevalent (94%), though few patients had a positive result (9%). Almost half of patients (47%) were tested for FRα expression, of which 35% had high expression, with 8% of patients treated with mirvetuximab soravtansine. Overall, 39% of patients initiated a non-platinum chemotherapy while 21% initiated a platinum-based chemotherapy; majority of all chemotherapy regimens were in combination with bevacizumab (66%). The time-to-event analyses revealed short rwTTD (3.3 [2.9, 3.7]), and rwTTNT (5.6 [4.9, 6.9]), and rwOS (median: 12.6 months [10.7, 16.6]).
CONCLUSIONS: In a real-world US PROC population, rwOS, rwTTD, and rwTTNT remain suboptimal, reflecting a high unmet need amid a diverse treatment landscape.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
CO182
Topic
Clinical Outcomes
Topic Subcategory
Clinical Outcomes Assessment
Disease
SDC: Oncology